DexCom (NASDAQ:DXCM) Coverage Initiated at Argus

Argus initiated coverage on shares of DexCom (NASDAQ:DXCM) in a research report issued to clients and investors on Thursday, Marketbeat.com reports. The firm set a “buy” rating and a $100.00 price target on the medical device company’s stock. Argus’ target price indicates a potential upside of 21.57% from the company’s previous close.

DXCM has been the subject of a number of other research reports. Canaccord Genuity Group reiterated a “buy” rating and set a $106.00 target price on shares of DexCom in a research note on Friday, August 1st. Citigroup reiterated a “buy” rating and set a $102.00 target price (up previously from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. UBS Group boosted their target price on shares of DexCom from $105.00 to $106.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. Morgan Stanley boosted their target price on shares of DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Finally, Barclays boosted their target price on shares of DexCom from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 30th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average price target of $99.89.

DexCom Stock Up 2.0%

DexCom stock opened at $82.26 on Thursday. DexCom has a twelve month low of $57.52 and a twelve month high of $93.25. The stock’s fifty day simple moving average is $82.81 and its 200-day simple moving average is $79.89. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $32.26 billion, a P/E ratio of 57.13, a P/E/G ratio of 1.69 and a beta of 1.43.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the company earned $0.43 earnings per share. The company’s revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, equities analysts expect that DexCom will post 2.03 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other news, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the sale, the director owned 33,411 shares in the company, valued at approximately $2,766,430.80. This represents a 9.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sadie Stern sold 6,184 shares of the stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total transaction of $526,320.24. Following the sale, the executive vice president owned 109,621 shares of the company’s stock, valued at $9,329,843.31. This trade represents a 5.34% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,906 shares of company stock worth $1,832,451. Insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On DexCom

Hedge funds have recently made changes to their positions in the business. Andra AP fonden acquired a new stake in shares of DexCom during the second quarter worth about $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of DexCom during the second quarter worth about $26,000. Golden State Wealth Management LLC boosted its stake in shares of DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after buying an additional 264 shares during the period. Zions Bancorporation National Association UT acquired a new stake in shares of DexCom during the first quarter worth about $27,000. Finally, Optiver Holding B.V. purchased a new position in DexCom during the fourth quarter worth about $33,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.